Healthcare News Pharma Industry News

World-first clinical trial for treating spinal cord injury using olfactory cell nerve bridges

Since the passing of Professor Emeritus Alan Mackay-Sim AM in 2023, his ground-breaking legacy research is about to be realised with a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury.

Griffith University researcher, Professor James St John, said olfactory ensheathing cells are the specialised cells within the olfactory (sense of smell) nerve within the nose that have numerous therapeutic properties for repairing and regenerating nerves.

Since the passing of Professor Emeritus Alan Mackay-Sim AM in 2023, his ground-breaking legacy research is about to be realised with a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury.

Griffith University researcher, Professor James St John, said olfactory ensheathing cells are the specialised cells within the olfactory (sense of smell) nerve within the nose that have numerous therapeutic properties for repairing and regenerating nerves.

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]